<DOC>
	<DOCNO>NCT01127984</DOCNO>
	<brief_summary>The aim study demonstrate efficacy fibrin sealant ( Tissucol-Baxter ) prevent pocket haematoma subsequent complication patient undergo pacemaker ICD implantation/replacement discontinue dual antiplatelet therapy ( i.e . ASA clopidogrel , ASA prasugrel ) anticoagulant therapy ( i.e . warfarin , heparin , low molecular weight heparin ) . Fibrin-based sealant available local haemostasis . A recent study ( Milic DJ et al , 2005 Europace , 7 : 374-379 ) show efficacy fibrin sealant prevention pacemaker pocket haematoma 40 patient undergoing pacemaker implantation receive anticoagulant treatment . Patients dual antiplatelet therapy ( DAT ) prone high risk bleed surgical procedure . Thus , routine use discontinuation DAT al least 4-7 day intervention . This practice may result high risk thrombotic event patient coronary stenting . Recently , Center start use fibrin sealant local haemostasis ( Tissucol Baxter ) , investigator observe reduction incidence pocket haematoma complication , need vacuum drainage system , reduction hospital stay .</brief_summary>
	<brief_title>Pocket Haematoma Prevention Patients Who Required Implantation/Replacement Pacemaker Implantable Cardiac Defibrillator . The PHP Study .</brief_title>
	<detailed_description>Purpose study . The purpose study demonstrate efficacy fibrin sealant ( Tissucol-Baxter ) prevention pocket haematoma subsequent complication patient required implantation/replacement pacemaker ICD wich discontinue dual antiplatelet anticoagulant therapy . Target . The primary endpoint test impact pocket haematoma patient treat tissucol compare conventional treatment vacuum drainage system without dual antiplatelet anticoagulant therapy discontinuation . The secondary endpoint compare length hospitalization two group . Type study . Prospective , randomize , single center , open label . Materials method . Will consecutively enrol approximately 100 patient . Inclusion criterion : patient age eighteen require initial implantation replacement device ( pacemaker , biventricular pacemaker , ICD ) treat : - dual antiplatelet therapy ( clopidogrel prasugrel ticlopidine , acetylsalicylic acid ) - anticoagulant ( warfarin heparin low molecular weight heparin ) . Patients Do discontinue antiplatelet anticoagulant therapy . According randomization list , patient assign tissucol treatment vacuum drainage system : - 50 patient : treat local application tissucol pocket pacemaker/ICD ; - 50 patient : treat vacuum drainage system .</detailed_description>
	<mesh_term>Hematoma</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<criteria>Patients require initial implantation replacement device ( pacemaker , biventricular pacemaker , implantable cardiac defibrillator ) treat : Dual antiplatelet therapy ( i.e . ASA clopidogrel , ASA prasugrel ) Anticoagulant therapy ( warfarin , heparin , LMWH ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>pacemaker</keyword>
	<keyword>pocket haematoma</keyword>
	<keyword>antiplatelet therapy</keyword>
	<keyword>fibrin glue</keyword>
</DOC>